Quarterly report pursuant to Section 13 or 15(d)

Acquisition Of Patents And Intangibles

v3.21.4
Acquisition Of Patents And Intangibles
6 Months Ended
Nov. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Acquisition of Patents and Intangibles

Note 8. Acquisition of Patents and Intangibles

The following table presents intangible assets as of November 30, 2021 and May 31, 2021, inclusive of patents:

(in thousands)

    

November 30, 2021

    

May 31, 2021

Leronlimab (PRO 140) patent

$

3,500

$

3,500

ProstaGene, LLC intangible asset acquisition, net of impairment

 

2,926

2,926

Website development costs

 

20

 

20

Gross carrying value

6,446

6,446

Accumulated amortization, net of impairment

 

(5,293)

 

(4,793)

Total amortizable intangible assets, net

$

1,153

$

1,653

Amortization expense related to all intangible assets was approximately $0.2 million and $0.5 million and $0.5 million and $1.0 million for the three and six months ended November 30, 2021 and 2020, respectively. The Company recognized an impairment charge of approximately $10.0 million related to the ProstaGene, LLC intangible asset acquisition during the third quarter of the year ended May 31, 2021. See the Company’s 2021 Form 10-K for additional discussion.

The following table summarizes the estimated aggregate future amortization expense related to the Company’s intangible assets with finite lives as of November 30, 2021:

Fiscal Year (in thousands)

    

Amount

2022 (6 months remaining)

$

221

2023

217

2024

85

2025

85

Thereafter

545

Total

$

1,153